• Engage the manufacturer to create public education campaigns for LAIV.

  • Educate healthcare providers and the public about the safety of the nasal spray vaccine.

  • Clinics and healthcare providers should consider (in a shortage situation) how nasal spray vaccine will be given unless contraindicated.

  • Refer to “nasal spray vaccine” instead of “live attenuated.”



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement